SB 34

  • Delaware Senate Bill
  • 150th General Assembly (2019-2020)
  • Introduced in Senate Apr 11, 2019
  • Passed Senate Apr 09, 2019
  • Passed House May 16, 2019
  • Governor

An Act To Amend Title 16 Of The Delaware Code Creating A Prescription Opioid Impact Fund.

Abstract

This Act creates a Prescription Opioid Impact Fund (“Fund”) through a prescription opioid impact fee (“Fee”) that is paid by pharmaceutical manufacturer. The anticipated revenue from the Fee is $2.8 million in 2020, $2.7 million in 2021, and $2.5 million in 2022.: 1. The fee is based on the total of the Morphine Milligram Equivalent (“MME”) in each manufacturer’s products dispensed in Delaware, based upon data already reported to the Prescription Monitoring Program (“PMP”). The PMP data contains the mandatory reports by pharmacists of every prescription opioid dispensed in the State. The PMP data does not include prescription opioids administered in hospitals, provided directly to patients by hospice, or dispensed by veterinarians. 2. The fee is assessed on manufacturers who exceed a threshold of 100,000 MMEs dispensed each quarter. 3. The Fee is calculated at a rate of either 1 penny per MME for a name brand prescription opioid dispensed and reported in the PMP or ¼ of a penny per MME for a prescription opioid that is a generic. The Act also provides that Secretary of the Department of Health and Social Services, after receiving recommendations from the Behavioral Health Consortium, the Addiction Action Committee, and the Overdose System of Care Committee, will award grants and contracts from the money in the Fund for the following activities: 1. Opioid addiction prevention. 2. Opioid addiction services, including the following: 3. Inpatient and outpatient treatment programs and facilities, including short-term and long-term residential treatment programs and sober living facilities. 4. Treating substance use disorder for the under-insured and uninsured. 5. Emergency assistance relating to prescription opioids, including purchasing Naloxone. 6. Administrative costs of implementing the Fee and Fund, up to 15% of the amount in the Fund. Finally, this Act expires in 5 years, unless terminated sooner or extended by the General Assembly, so that the Fee is only continued if it is effective and is not creating negative unintended consequences.

Bill Sponsors (22)

Stephanie L. Hansen

  • Democratic
  • upper
  • 10
Primary

Anthony Delcollo

  • Republican
  • upper
  • 7
Primary

David Bentz

  • Democratic
  • lower
  • 18
Primary

Kevin S Hensley

  • Republican
  • lower
  • 9
Primary

Bruce C. Ennis

  • Democratic
  • upper
  • 14
Cosponsor

S. Elizabeth Lockman

  • Democratic
  • upper
  • 3
Cosponsor

David B. McBride

  • Democratic
  • upper
  • 13
Cosponsor

Harris B. McDowell

  • Democratic
  • upper
  • 1
Cosponsor

Trey Charles Paradee

  • Democratic
  • upper
  • 17
Cosponsor

Nicole Poore

  • Democratic
  • upper
  • 12
Cosponsor

David P. Sokola

  • Democratic
  • upper
  • 8
Cosponsor

Laura Sturgeon

  • Democratic
  • upper
  • 4
Cosponsor

Bryan Townsend

  • Democratic
  • upper
  • 11
Cosponsor

John Walsh

  • Democratic
  • upper
  • 9
Cosponsor

Paul S. Baumbach

  • Democratic
  • lower
  • 23
Cosponsor

Gerald L. Brady

  • Democratic
  • lower
  • 4
Cosponsor

Sherry Dorsey Walker

  • Democratic
  • lower
  • 3
Cosponsor

Debra Heffernan

  • Democratic
  • lower
  • 6
Cosponsor

Edward S. Osienski

  • Democratic
  • lower
  • 24
Cosponsor

Raymond Seigfried

  • Democratic
  • lower
  • 7
Cosponsor

Michael F. Smith

  • Republican
  • lower
  • 22
Cosponsor

Kimberly Williams

  • Democratic
  • lower
  • 19
Cosponsor

Votes


May 16, 2019

3/5

Pass

House

Apr 09, 2019

3/5

Pass

Senate

Actions


Jun 12, 2019

Office of the Governor

Signed by Governor

May 16, 2019

House

Passed By House. Votes: 33 YES 8 NO

May 08, 2019

House

Reported Out of Committee (Health & Human Development) in House with 1 Favorable, 6 On Its Merits

  • Committee-Passage
  • Committee-Passage-Favorable
Health & Human Development

Apr 11, 2019

House

Assigned to Health & Human Development Committee in House

  • Introduction
  • Referral-Committee
Health & Human Development

Apr 09, 2019

Senate

Passed By Senate. Votes: 17 YES 4 NO

Senate

Amendment SA 1 to SB 34 - Passed By Senate. Votes: 19 YES 2 NO

Mar 27, 2019

Senate

Reported Out of Committee (Health & Social Services) in Senate with 1 Favorable, 3 On Its Merits

  • Committee-Passage
  • Committee-Passage-Favorable
Health & Social Services

Mar 12, 2019

Senate

Introduced and Assigned to Health & Social Services Committee in Senate

  • Introduction
  • Referral-Committee
Health & Social Services

Bill Text

Bill Text Versions Format
SA 1 to SB 34 PDF HTML
Bill Text HTML PDF

Related Documents

Document Format
Fiscal Note PDF

Sources

Data on Open States is updated nightly from the official website of the Delaware General Assembly.

If you notice any inconsistencies with these official sources, feel free to file an issue.